Neuralstem ALS Trial Data Presented at the American Association of Neurological Surgeons Annual Meeting

“That our cells and method of delivery are safe in ALS patients bodes very well for expanding to other indications. We expect to commence our FDA-approved Phase I trial in chronic spinal cord injury later this year using the same methodology. We want to thank the surgeons at Emory, who developed these techniques, as well as the patients and their families who have taken part in the trial.”

No Evidence of Benefit of Lithium on Survival in Patients with ALS

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
From the UKMND-LiCALS Study Group
Summary article posted online in The Lancet Neurology, February 27, 2013 •

Background

Lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a [...]

Neuralstem Looks to Include Efficacy in Phase I Trial

Company requesting permission to evaluate efficacy in its phase 1 safety trial, as well as to increase the dosage and number of trial participants.